The FDA approved Abbott's Tendyne minimally invasive heart replacement for mitral valve disease that could disqualify ...

The approval is tightly defined: the system will be for patients ineligible for surgery and with anatomy unfavorable for TEER ...

Abbott (NYSE: ABT) announced today that it received FDA approval for its Tendyne transcatheter mitral valve replacement (TMVR ...

The Tendyne system is designed for those who are considered high-risk for traditional open-heart surgery and for whom mitral valve repair with Abbott’s MitraClip is not a viable option.

Abbott Laboratories (NYSE:ABT) has received FDA approval today for its Tendyne™ transcatheter mitral valve replacement (TMVR) ...

The FDA gave the OK for the North Chicago-based medical device maker's Tendyne transcatheter mitral valve replacement.

The system is available for patients whose mitral valves are not working properly due to severe mitral annular calcification.

Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne™ transcatheter mitral valve replacement (TMVR) system to treat people with mitral ...

The Tendyne system replaces mitral valves that are not functioning properly due to a buildup of calcium in the base of the valves, known as severe mitral annular calcification (MAC) Tendyne ...

ABBOTT PARK, Ill. - Abbott Laboratories (NYSE: ABT), a prominent player in the Healthcare Equipment & Supplies industry with a market capitalization of $228 billion, has received approval from the U.S ...